ID   Tanoue
AC   CVCL_1852
SY   TANOUE
DR   CLO; CLO_0009269
DR   CLO; CLO_0050979
DR   EFO; EFO_0002380
DR   ArrayExpress; E-MTAB-38
DR   BioGRID_ORCS_Cell_line; 1759
DR   BioSample; SAMN03472169
DR   BioSample; SAMN03473578
DR   cancercelllines; CVCL_1852
DR   Cell_Model_Passport; SIDM00288
DR   Cosmic; 1012122
DR   Cosmic; 1130258
DR   Cosmic; 1281385
DR   DepMap; ACH-001669
DR   DSMZ; ACC-399
DR   DSMZCellDive; ACC-399
DR   GEO; GSM5137747
DR   IARC_TP53; 21631
DR   IGRhCellID; TANOUE
DR   LINCS_LDP; LCL-1095
DR   PRIDE; PXD023662
DR   Progenetix; CVCL_1852
DR   RCB; RCB1180
DR   Wikidata; Q54971725
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7538617;
RX   PubMed=15843827;
RX   PubMed=15901131;
RX   PubMed=16408098;
RX   PubMed=20215515;
RX   PubMed=24590883;
RX   PubMed=28196595;
RX   PubMed=35354797;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: ~48 hours (PubMed=7538617); ~40 hours (DSMZ=ACC-399).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Heterozygous (PubMed=15901131; DepMap).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DepMap; DSMZ; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 10,12,13,14 (DepMap)
ST   D16S539: 12,13 (DSMZ; RCB)
ST   D18S51: 13,14
ST   D19S433: 15,16
ST   D21S11: 29,30
ST   D2S1338: 18,19
ST   D3S1358: 15,16
ST   D5S818: 10,11,12 (DepMap; RCB)
ST   D5S818: 11,12 (DSMZ)
ST   D7S820: 10,11
ST   D8S1179: 14,15
ST   FGA: 19,22,23 (DepMap)
ST   FGA: 14,22,23 (DSMZ)
ST   Penta D: 11,13
ST   Penta E: 14,18,19
ST   TH01: 7,10
ST   TPOX: 11
ST   vWA: 14,18,19 (DepMap; RCB)
ST   vWA: 14,19 (DSMZ)
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7538617; DOI=10.1016/0145-2126(94)00156-5;
RA   El-Sonbaty S.S., Tsuchiya H., Watanabe M., Hochito K., Kunisada T.,
RA   Shimosaka A., Matsuda I.;
RT   "Exogenous expression of human granulocyte colony-stimulating factor
RT   receptor in a B-lineage acute lymphoblastic leukemia cell line: a
RT   possible model for mixed lineage leukemia.";
RL   Leuk. Res. 19:249-256(1995).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//